Table 1 Demographic and clinical parameter, treatment and outcome of children and adolescents in the study sample
Parameter | Patients ≥ 12 years | Patients < 12 years |
|---|---|---|
N | 674 | 682 |
Female subjects, n (%) | 456 (67.7) | 483 (70.8) |
Age, years, mean (SD) | 15.2 (1.9) | 7.2 (2.9) |
Age at disease onset, years, mean (SD) | 8.8 (4.9) | 4.3 (2.8) |
Disease duration, years, mean (SD) | 6.4 (4.9) | 2.9 (2.7) |
Diagnoses, n (%) | ||
JIA | 6201 | 6592 |
Systemic arthritis | 24 (3.6) | 34 [5] |
Oligoarthritis, extended | 73 (10.8) | 64 (9.4) |
Oligoarthritis, persistent | 214 (31.8) | 355 (52) |
Psoriatic arthritis | 44 (6.5) | 24 (3.5) |
Enthesitis-related arthritis | 85 (12.6) | 19 (2.8) |
Polyarthritis, seropositive | 19 (2.8) | 11 (1.6) |
Polyarthritis, seronegative | 127 (18.8) | 124 (18.2) |
Other arthritis | 26 (3.9) | 21 (3.1) |
Systemic lupus erythematosus | 42 (6.2) | 6 (0.9) |
Juvenile dermatomyositis | 12 (1.8) | 17 (2.5) |
ANA positive/tested, n (%) | 341/556; (61) | 37/524; (71) |
Therapy, n (%)* | ||
DMARD | 352 (55.5) | 346 (55) |
sDMARD | 262 (41.3) | 290 (46.1) |
bDMARD | 195 (30.8) | 124 (19.7) |
Systemic glucocorticoids | 35 (6.2) | 24 (4.8) |
Outcome parameter | ||
PhGA disease activity, NRS, mean (SD) | 1.3 (1.8) | 1.5 (2.2) |
Joint count, mean (SD)# | 1.1 (2.9) | 1.2 (3.3) |
Functional status, CHAQ (0–3), mean (SD) | 0.2 (0.5) | 0.3 (0.5) |
PGA, NRS, mean (SD) | 2.3 (2.5) | 2.1 (2.5) |